Heartbeam, Inc. current report, 18 January 2023

Full document

HeartBeam, Inc. Form 8-K Summary

Business context and reporting period

HeartBeam, Inc. filed a Current Report on Form 8-K under Item 5.02. The earliest reported event occurred on January 18, 2023; the report was signed and filed on January 24, 2023. The filing concerns the appointment and employment agreement of Robert P. Eno as President.

Key financial and compensation terms

  • Annual base compensation: $360,000, payable semi-monthly.
  • Potential incentive bonus: 40% of annual base salary, based on agreed corporate goals and objectives.
  • Additional employee benefits may be provided under the Company’s applicable policies.
  • The Board approved an option to purchase 240,000 shares of common stock under the Company’s 2022 Stock Plan.
  • The option exercise price is the fair market value determined by the Board or Compensation Committee at the time of grant; the filing text does not provide a clear exercise price, vesting schedule, or expiration date.
  • The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating performance metrics.

Material changes versus the prior comparable period

Mr. Eno became President effective January 18, 2023. The filing does not present comparative financial information or describe other material operating changes.

Management commentary, risks, and unusual items

  • Mr. Eno has more than 28 years of medical technology senior-management experience, including prior roles at PreView Medical, HeartFlow, and OptiMedica.
  • The new compensation arrangement creates ongoing cash compensation obligations and potential equity dilution through the stock option.
  • The filing states that Mr. Eno has no family relationship with current officers or directors and no reportable related-party transactions under Item 404(a) of Regulation S-K.
  • The detailed employment agreement, filed as Exhibit 10.2, governs the full rights and obligations of the parties.
  • A press release announcing the appointment was filed as Exhibit 99.1.

Important facts for investors to verify

  • Review Exhibit 10.2 for termination provisions, severance, bonus conditions, benefits, option vesting, and change-in-control terms.
  • Confirm the option’s fair-market-value exercise price and resulting potential dilution.
  • Assess the effect of the $360,000 annual salary and potential bonus on the Company’s cash runway and future liquidity.
  • Review subsequent filings for changes to Mr. Eno’s role, compensation, or equity award.